Le Lézard
Classified in: Health
Subjects: PDT, MAT

Medical Marijuana, Inc. Subsidiary Dixie Botanicals® Announces Release of New Flavored CBD Vape Liquids


SAN DIEGO, Nov. 15, 2018 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first publicly traded cannabis company in the United States, announced today that its subsidiary Dixie Botanicals® has released a new line of flavored cannabidiol (CBD) vaporizer (vape) liquids.

Dixie Vape Liquids

Dixie Botanicals® CBD Vape Liquid (link to website) is an exclusive CBD product line that gives users the opportunity to consume CBD in a quick and efficient way. Each pre-filled 30ml dropper bottle contains 1000 mg of high-quality CBD isolate and is available in 3 flavors: Blackberry Lemonade, Vanilla Caramel and Sour Watermelon.

"The company is delighted to offer this new CBD vape liquid product for those who want a tasty and efficient way to consume CBD," said Medical Marijuana, Inc. CEO Dr. Stuart Titus. "Each variety is made with natural CBD isolate and is a great option for those looking to change up their CBD intake method with a delicious, casual and convenient alternative."

Dixie Botanicals® CBD Vape Liquids can be used with most liquid-compatible vape pens on the market. Dixie Botanicals is excited to offer our new CBD Vape Liquid bundled with the popular Special K Vaporizer or RUBI Vaporizer from KandyPens® for an ideal CBD vaping experience.  

Dixie Botanicals® products are created using CBD oil extracted from non-GMO hemp plants. These plants are grown in Europe, free of herbicides, pesticides and chemical fertilizers, providing consumers with the purest product available. As a nutritional supplement, it's an incredible source of omega fatty acids, vitamins, amino acids, chlorophyll, and terpenes.

Learn more about the Dixie Botanicals® CBD Vape Liquid and other exciting CBD hemp oil products at DixieBotanicals.com

Dixie Botanicals® CBD Vape Liquid can also available for purchase by retailers through HempMeds at HempMeds.com.

About Dixie Botanicals®
Launched in 2012, Dixie Botanicals® was the first mainstream hemp-based CBD brand available on the market. Regarded as one of the most well recognized brands in the industry, Dixie Botanicals® offers innovative CBD hemp oil products for active consumers who are looking perform at their best. Dixie Botanicalstm products contain naturally occurring cannabidiol (CBD) hemp oil from the mature stalk of the industrial hemp plant. All our products are Triple Lab Testedtm, ensuring that every natural product we offer is free from contaminants and of the highest quality possible. For more information, visit: www.DixieBotanicals.com.

About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

CONTACT:
Public Relations Contact:

Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
[email protected]
www.cmwmedia.com

 

SOURCE Medical Marijuana, Inc.


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...

at 08:00
Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that two abstracts have been accepted for oral presentation at the...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: